中金发表研究报告指,和黄医药(00013.HK) 2025财年收入5.49亿美元,按年跌13%;其中肿瘤免疫板块综合收入2.85亿美元。归母净利润4.57亿美元,剔除出售上海和黄股权影响,净利润约0.41亿美元,符合预期。公司指引2026年肿瘤免疫板块综合收入3.3至4.5亿美元,略超预期,主要由于潜在研发收入可能超预期。该行指,考虑到公司营运效率和盈利能力不断提高,将今年净利润预测上调59%至5...
Source Link中金发表研究报告指,和黄医药(00013.HK) 2025财年收入5.49亿美元,按年跌13%;其中肿瘤免疫板块综合收入2.85亿美元。归母净利润4.57亿美元,剔除出售上海和黄股权影响,净利润约0.41亿美元,符合预期。公司指引2026年肿瘤免疫板块综合收入3.3至4.5亿美元,略超预期,主要由于潜在研发收入可能超预期。该行指,考虑到公司营运效率和盈利能力不断提高,将今年净利润预测上调59%至5...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.